Finding new drugs to stop the spread of treatment-resistant brain cancer cells.
High-throughput Identification and Validation of Drugs to Target Migrating and Treatment-Resistant Glioblastoma Cells
This study is looking for new ways to stop the spread of glioblastoma, a tough type of brain cancer, by testing new drugs that could help make treatment more effective and improve survival for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Arlington NIH-funded |
| Lab location | 1 site (Arlington, United States) |
| Project ID | NIH-11043851 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a type of brain cancer known for its aggressive spread into surrounding brain tissue. Current treatments have limited effectiveness, leading to poor survival rates. The research team is developing advanced methods to identify and validate new drugs that can effectively block the migration of these cancer cells. By using innovative high-throughput screening techniques, they aim to create a more effective treatment strategy that could transform glioblastoma into a more manageable condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma, particularly those whose tumors are resistant to current treatments.
Not a fit: Patients with non-cancerous brain conditions or those with glioblastoma that has not spread may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates and quality of life for patients with glioblastoma.
How similar studies have performed: Previous research has shown promise in targeting cancer cell migration, indicating that this approach could lead to significant advancements in glioblastoma treatment.
Where this research is happening
Arlington, United States
- University of Texas Arlington — Arlington, United States (Active)
Researchers
- Principal investigator: Kim, Young-Tae — University of Texas Arlington
- Study coordinator: Kim, Young-Tae
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.